Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort.
Anti-phospholipid antibodies are common in patients in the Hopkins' Lupus Cohort: 47% have anti-cardiolipin, 32.5% anti-beta(2)-glycoprotein I and 26% lupus anticoagulant (by dRVVT confirmatory testing). Systemic lupus erythematosus patients with the lupus anticoagulant at baseline have a 50% chance of a deep venous thrombosis/pulmonary embolus in the next 20 years. Anti-phospholipid antibodies differ in their association with thrombosis: the lupus anticoagulant is most strongly associated with arterial and venous thrombosis and is the only anti-phospholipid antibody associated with myocardial infarction. Anti-phospholipid antibodies are not associated with atherosclerosis.
Petri
M
M
Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland 21205, USA. mpetri@jhmi.edu
D017153:Antibodies, Anticardiolipin / Q000276:immunology; D017152:Antibodies, Antiphospholipid / Q000276:immunology*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D016682:Lupus Coagulation Inhibitor / Q000276:immunology*; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000276:immunology*; D008297:Male; D009203:Myocardial Infarction / Q000453:epidemiology / Q000209:etiology; D011655:Pulmonary Embolism / Q000453:epidemiology / Q000209:etiology; D013927:Thrombosis / Q000453:epidemiology / Q000209:etiology; D013997:Time Factors; D053482:beta 2-Glycoprotein I / Q000276:immunology
D017153:Antibodies, Anticardiolipin; D017152:Antibodies, Antiphospholipid; D016682:Lupus Coagulation Inhibitor; D053482:beta 2-Glycoprotein I